Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OCULAR THERAPEUTIX, INCOCUL · Entity 273 | Global CCO | January 21, 2026 | January 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OCULAR THERAPEUTIX, INC
Report date January 21, 2026 · Filed January 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 136,000 |
Reported balance
After 2026-01-21 transaction · row 1
1 source rowRow 1 · 2026-01-21 · Grant · Acquired 136,000 · Balance 136,000 F1: On January 21, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2019 Inducement Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.42 · Expires 2036-01-20 | Direct | 416,000 |
Reported balance
After 2026-01-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-21 · Grant · Acquired 416,000 · Balance 416,000 F2: This option was granted on January 21, 2026 and vests over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the reporting person's first date of employment and the remainder vesting in equal monthly installments over the three years after such date. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 21, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2019 Inducement Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
F2: This option was granted on January 21, 2026 and vests over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the reporting person's first date of employment and the remainder vesting in equal monthly installments over the three years after such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 21, 2026 Filed Jan 27, 2026 00:15 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 416,000 | $0.00 Strike: $11.42 | $0.00 |
DisclosureSEC source: 0001104659-26-006711 · tm263977-2_4seq1.xml · derivative · entry 2 Robinson David Wayne · CIK 0002107335 · Global CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,000 Underlying: Common Stock · 416,000 shares Expires 2036-01-20 F2 · derivative.exercise_date: This option was granted on January 21, 2026 and vests over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the reporting person's first date of employment and the remainder vesting in equal monthly installments over the three years after such date. Read SEC document |
| January 21, 2026 Filed Jan 27, 2026 00:15 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 136,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-006711 · tm263977-2_4seq1.xml · nonDerivative · entry 1 Robinson David Wayne · CIK 0002107335 · Global CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,000 F1 · shares: On January 21, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2019 Inducement Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.